Skip to content

Oxford Nanopore: why are investors still so negative on this genetech giant?


This morning Oxford Nanopore (LSE: ONT) reported FY21 results, with group revenue surpassing company guidance, and gross margins increasing as customers start ramping up their use of acquired instruments. While Oxford Nanopore expects a significant decline in Covid sequencing revenue, the company has nevertheless improved their FY22 outlook.

"Investors will be paying close attention to the continued customer base growth, potential for additional population genomics studies, continued accuracy and cost improvements, and the establishment of Oxford Nanopore’s Diagnostics team in an effort to bring this technology closer to the patient," noted Sebastian Skeet, senior analyst covering the global healthcare sector at Third Bridge.

Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.

Log In or Sign Up to Armchair Trader+

Already a member? Log in here:

Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets
Back To Top